Capital investment aimed at developing high-value-added products and strengthening competitiveness
First written in FY2016. 7 of 18 entries say "Advanced", first in FY2017. Latest entry: 2026-08-07.
6 other companies' latest entry also says "Achieved".
- FY2026AdvancedAnnual report
「The Group made ¥10,706 million in capital investments, primarily for capacity expansion facilities in Chemical Materials and the rationalization of various product manufacturing facilities.」
Capital investment totaled ¥10,706 million. Specific plans through 2027 were also presented, including a pharmaceutical excipient production facility at the Nihongi Plant, a boiler at the Takaoka Plant, and capacity expansion and rationalization of production facilities at each plant. - FY2026-H1Continued capital investment and increase in construction in progressAnnual report
「Expenditures for the acquisition of property, plant and equipment ¥6,985 Construction in progress 12,179 15,368」
Expenditures for the acquisition of property, plant and equipment during the interim period totaled ¥6,985 million, and construction in progress increased by ¥3,188 million from the end of the previous fiscal year. Capital investment continued, and the increase in facilities under construction was reflected in the balance sheet. - FY2025-H1Increase in capital investment expenditures and construction in progressAnnual report
「Expenditures for the acquisition of property, plant and equipment ¥7,405 / Construction in progress 3,379 8,234」
Expenditures for the acquisition of property, plant and equipment during the interim period totaled ¥7,405 million, while construction in progress increased from ¥3,379 million at the end of the previous fiscal year to ¥8,234 million. Progress in capital investment was reflected in the balance sheet and cash flows. - FY2024Decrease in capital investment and update of new construction plansAnnual report
「The Group made ¥7,484 million in capital investments, primarily for mass-production facilities and the rationalization of various production facilities. / Company / Nihongi Plant / Chemical Materials / Pharmaceutical excipient production facility / ¥10,500 million / Internal funds / January 2023 / August 2026 / Company / Chiba Plant / Chemical Materials / Functional chemicals production facility / ¥2,500 million / Internal funds / January 2023 / February 2025」
Capital investment decreased from ¥13,113 million in the previous fiscal year to ¥7,484 million, while specific new construction plans were presented, including a ¥10.5 billion pharmaceutical excipient facility at the Nihongi Plant and a ¥2.5 billion functional chemicals facility at the Chiba Plant. - FY2022Increase in capital expenditureAnnual report
「The Group made ¥13,113 million in capital investments, primarily for capacity expansion facilities in the Chemicals business, mass-production facilities for new products in the Agricultural Chemicals business, and the rationalization of various production facilities.」
Capital investment increased from ¥7,718 million in the previous fiscal year to ¥13,113 million. ¥9,817 million was invested in capacity expansion facilities for pharmaceutical excipients and other projects in the Chemicals business. - FY2022-Q3RestatedAnnual report
「As a result of the start of operations at the capacity expansion facility for the pharmaceutical excipient “NISSO HPC,” construction in progress decreased by ¥2,408 million, machinery and equipment and vehicles increased by ¥3,478 million, and buildings and structures increased by ¥2,123 million.」
The decrease in construction in progress and the recognition of fixed assets associated with the start of operations at the NISSO HPC capacity expansion facility continue to be disclosed. This is not a new disclosure of the start of operations. - FY2022-Q2RestatedAnnual report
「As a result of the start of operations at the capacity expansion facility for the pharmaceutical excipient “NISSO HPC,” among other factors, construction in progress decreased by ¥3,973 million, machinery and equipment and vehicles increased by ¥3,608 million, and buildings and structures increased by ¥2,001 million.」
The recognition of capital expenditures after the capacity expansion facility for NISSO HPC began operations is being reconfirmed. This is not a new disclosure of the start of operations. - FY2022-Q1AdvancedAnnual report
「Construction in progress decreased by ¥5.13 billion following the start of operations at expanded production facilities for the pharmaceutical excipient “NISSO HPC.” Machinery and equipment increased by ¥3.03 billion, while buildings and structures increased by ¥2.142 billion.」
The capacity expansion facility for NISSO HPC became operational as part of capital investment to expand production capacity for high-value-added products. - FY2021Decrease in capital investment and addition of new construction plansAnnual report
「The Group made ¥7,718 million in capital investments, primarily for the development of high-value-added products and the strengthening of competitiveness.」
Capital investment decreased from ¥8,824 million in the previous fiscal year to ¥7,718 million. Meanwhile, new plans were added at the Nihongi Plant for a ¥1.3 billion production technology research building and a ¥6.1 billion pesticide active ingredient production facility, while existing plans, including the ¥5.4 billion pharmaceutical excipient production facility, continued. - FY2020AdvancedAnnual report
「The Group made ¥8,824 million in capital investments, primarily for the development of high-value-added products and the strengthening of competitiveness. / Nihongi Plant / Pharmaceutical excipient production facility / ¥5,400 million / Work to begin November 2018 / Completion scheduled for March 2021 / Nihongi Plant / Functional chemicals production facility / ¥900 million / Work to begin December 2019 / Completion scheduled for March 2021」
Annual capital investment increased from ¥8,026 million in the previous fiscal year to ¥8,824 million. Plans to construct new pharmaceutical excipient and functional chemicals production facilities at the Nihongi Plant were also continued and added. - FY2019AdvancedAnnual report
「The Group made ¥8,026 million in capital investments, primarily for construction of a research and development building, the development of high-value-added products and the strengthening of competitiveness.」
In addition to making ¥8,026 million in capital investments during the year, the Company formalized a plan to construct a new ¥5.4 billion pharmaceutical excipient production facility at the Nihongi Plant, with work scheduled to begin in November 2018 and completion scheduled for March 2021. - FY2018AdvancedAnnual report
「The Group made ¥8,589 million in capital investments, primarily for the development of high-value-added products and the strengthening of competitiveness.」
Capital investment totaled ¥8,589 million. In addition, plans were formalized for a ¥600 million research and development building at the Takaoka Plant and for capacity expansion and rationalization at the Nihongi, Takaoka, Chiba and other plants from April 2018 through March 2019. - FY2017AdvancedAnnual report
「Company; Chiba Plant; Chemicals Business; semiconductor materials manufacturing equipment; ¥1,000 million; internal funds; February 2017; June 2018」
As a capital investment aimed at developing high-value-added products and strengthening competitiveness, plans for a new ¥1,000 million semiconductor materials production facility at the Chiba Plant were formalized, with work scheduled to begin in February 2017 and completion scheduled for June 2018. - FY2016First statedAnnual report
「The Group made capital investments of ¥6,764 million, primarily for the development of high-value-added products and the strengthening of competitiveness.」
Capital investment during the consolidated fiscal year was ¥6,764 million, focused primarily on strengthening and rationalizing manufacturing facilities and carrying out maintenance and replacement.